Guizhou Yibai Pharmaceutical Co., Ltd.
SSE:600594.SS
3.94 (CNY) • At close June 6, 2025
Overview | Financials
Numbers are in millions (except for per share data and ratios) CNY.
| 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2004 | 2003 | 2002 | 2001 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue
| 2,174.032 | 2,777.902 | 2,735.263 | 3,346.705 | 3,413.193 | 3,361.026 | 3,882.863 | 3,807.662 | 3,686.823 | 3,302.519 | 3,157.075 | 2,784.9 | 2,252.575 | 1,903.335 | 1,467.465 | 1,307.4 | 1,153.938 | 1,006.319 | 717.18 | 739.373 | 631.907 | 502.666 | 443.78 | 276.532 |
| Cost of Revenue
| 829.44 | 935.744 | 794.229 | 711.052 | 707.301 | 735.602 | 1,075.842 | 961.511 | 867.809 | 632.283 | 571.322 | 496.826 | 417.16 | 326.99 | 335.41 | 362.156 | 280.583 | 257.794 | 186.845 | 209.706 | 190.075 | 228.94 | 257.648 | 161.176 |
| Gross Profit
| 1,344.592 | 1,842.159 | 1,941.034 | 2,635.652 | 2,705.892 | 2,625.424 | 2,807.021 | 2,846.151 | 2,819.014 | 2,670.236 | 2,585.753 | 2,288.074 | 1,835.416 | 1,576.345 | 1,132.055 | 945.243 | 873.354 | 748.524 | 530.335 | 529.668 | 441.832 | 273.726 | 186.132 | 115.355 |
| Gross Profit Ratio
| 0.618 | 0.663 | 0.71 | 0.788 | 0.793 | 0.781 | 0.723 | 0.747 | 0.765 | 0.809 | 0.819 | 0.822 | 0.815 | 0.828 | 0.771 | 0.723 | 0.757 | 0.744 | 0.739 | 0.716 | 0.699 | 0.545 | 0.419 | 0.417 |
| Reseach & Development Expenses
| 100.502 | 118.063 | 126.933 | 136.075 | 145.999 | 118.549 | 76.775 | 71.405 | 75.379 | 38.722 | 22.78 | 10.103 | 3.099 | 2.158 | 8.394 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| General & Administrative Expenses
| 160.838 | 147.513 | 157.349 | 185.243 | 171.418 | 162.166 | 190.802 | 173.62 | 142.116 | 127.442 | 99.133 | 76.214 | 66.308 | 63.95 | 59.968 | 119.097 | 104.957 | 98.212 | 77.789 | 62.354 | 42.415 | 23.941 | 19.103 | 15.791 |
| Selling & Marketing Expenses
| 903.481 | 1,032.632 | 1,195.796 | 1,612.392 | 1,672.357 | 1,788.971 | 1,932.265 | 1,834.502 | 1,836.939 | 2,044.68 | 1,747.371 | 1,528.083 | 1,248.711 | 1,085.596 | 708.343 | 633.775 | 601.976 | 528.379 | 563.759 | 385.81 | 318.283 | 172.149 | 103.635 | 59.773 |
| SG&A
| 1,064.319 | 1,586.728 | 1,353.144 | 1,797.635 | 1,843.775 | 1,951.137 | 2,123.068 | 2,008.121 | 1,979.055 | 2,172.122 | 1,846.504 | 1,604.297 | 1,315.02 | 1,149.546 | 768.311 | 752.873 | 706.933 | 626.591 | 641.549 | 448.165 | 360.699 | 196.09 | 122.738 | 75.563 |
| Other Expenses
| 492.025 | 0 | 191.519 | 200.141 | 213.93 | 225.814 | -7.996 | 20.219 | 23.677 | 40.639 | 38.626 | 22.846 | 23.149 | 14.398 | 6.034 | 9.803 | 0.412 | 39.191 | 9.569 | -0.558 | -7.876 | -0.347 | 6.465 | 4.082 |
| Operating Expenses
| 1,656.845 | 1,822.107 | 1,671.597 | 2,133.851 | 2,203.704 | 2,295.499 | 2,441.96 | 2,293.073 | 2,268.094 | 2,396.201 | 2,028.384 | 1,733.679 | 1,434.068 | 1,237.134 | 853.84 | 768.972 | 721.182 | 638.459 | 649.885 | 457.51 | 368.212 | 200.433 | 125.788 | 77.713 |
| Operating Income
| -312.253 | 145.513 | 257.331 | 536.134 | 486.564 | 377.77 | -777.95 | 466.314 | 463.928 | 194.538 | 524.131 | 492.994 | 381.011 | 310.692 | 219.364 | 135.14 | 116.715 | 70.285 | -144.308 | 61.881 | 66.509 | 61.121 | 53.806 | 36.621 |
| Operating Income Ratio
| -0.144 | 0.052 | 0.094 | 0.16 | 0.143 | 0.112 | -0.2 | 0.122 | 0.126 | 0.059 | 0.166 | 0.177 | 0.169 | 0.163 | 0.149 | 0.103 | 0.101 | 0.07 | -0.201 | 0.084 | 0.105 | 0.122 | 0.121 | 0.132 |
| Total Other Income Expenses Net
| -20.267 | -13.192 | -649.397 | -122.752 | -169.187 | -93.494 | -1,125.277 | -19.272 | -40.964 | -23.561 | 21.947 | -7.031 | -1.572 | 15.271 | -26.239 | -21.866 | -36.146 | 3.634 | 8.284 | -10.949 | -14.809 | -0.347 | -0.074 | 3.061 |
| Income Before Tax
| -332.521 | 132.321 | -392.066 | 310.365 | 297.472 | 208.323 | -785.947 | 486.533 | 483.34 | 227.333 | 556.526 | 515.49 | 403.931 | 325.068 | 211.104 | 144.842 | 116.579 | 109.477 | -134.965 | 61.266 | 58.72 | 60.774 | 53.732 | 39.682 |
| Income Before Tax Ratio
| -0.153 | 0.048 | -0.143 | 0.093 | 0.087 | 0.062 | -0.202 | 0.128 | 0.131 | 0.069 | 0.176 | 0.185 | 0.179 | 0.171 | 0.144 | 0.111 | 0.101 | 0.109 | -0.188 | 0.083 | 0.093 | 0.121 | 0.121 | 0.143 |
| Income Tax Expense
| 2.153 | 40.964 | 46.261 | 79.574 | 86.133 | 75.906 | -101.46 | 78.753 | 98.622 | 47.3 | 89.023 | 84.481 | 65.172 | 57.263 | 14.231 | 21.282 | 18.466 | 15.284 | 0.986 | 12.193 | 13.62 | 9.304 | 8.158 | 5.627 |
| Net Income
| -317.215 | 103.399 | -438.327 | 243.772 | 219.893 | 141.895 | -725.495 | 387.53 | 373.034 | 171.142 | 461.165 | 429.154 | 333.268 | 265.483 | 195.559 | 121.807 | 98.131 | 92.743 | -134.523 | 69.418 | 56.344 | 51.557 | 45.574 | 34.055 |
| Net Income Ratio
| -0.146 | 0.037 | -0.16 | 0.073 | 0.064 | 0.042 | -0.187 | 0.102 | 0.101 | 0.052 | 0.146 | 0.154 | 0.148 | 0.139 | 0.133 | 0.093 | 0.085 | 0.092 | -0.188 | 0.094 | 0.089 | 0.103 | 0.103 | 0.123 |
| EPS
| -0.4 | 0.13 | -0.55 | 0.31 | 0.29 | 0.18 | -0.92 | 0.49 | 0.49 | 0.24 | 0.6 | 0.6 | 0.46 | 0.38 | 0.28 | 0.26 | 0.14 | 0.17 | -0.29 | 0.098 | 0.061 | 0.08 | 0.097 | 0.072 |
| EPS Diluted
| -0.4 | 0.13 | -0.55 | 0.31 | 0.29 | 0.18 | -0.92 | 0.49 | 0.49 | 0.24 | 0.6 | 0.6 | 0.46 | 0.38 | 0.28 | 0.26 | 0.14 | 0.17 | -0.29 | 0.098 | 0.061 | 0.08 | 0.097 | 0.072 |
| EBITDA
| -113.436 | 355.071 | -122.811 | 552.278 | 519.85 | 452.059 | -483.23 | 735.628 | 674.715 | 384.576 | 686.026 | 584.053 | 467.215 | 396.154 | 277.441 | 212.152 | 195.782 | 138.927 | -87.365 | 106.174 | 86.626 | 81.128 | 66.257 | 43.066 |
| EBITDA Ratio
| -0.052 | 0.128 | -0.045 | 0.165 | 0.152 | 0.135 | -0.124 | 0.193 | 0.183 | 0.116 | 0.217 | 0.21 | 0.207 | 0.208 | 0.189 | 0.162 | 0.17 | 0.138 | -0.122 | 0.144 | 0.137 | 0.161 | 0.149 | 0.156 |